HLB Therapeutics Co.,Ltd.
115450
株式のランク
#18716
HLB Therapeutics Co.,Ltd. operates as a biotechnology company, focusing on the... HLB Therapeutics Co.,Ltd. operates as a biotechnology company, focusing on the creation of pharmaceutical products for both the South Korean and international markets. A significant part of its research and development initiatives includes GBT-201, a compound utilizing Thymosin beta designed to treat various eye ailments such as dry eye syndrome and neurotrophic keratopathy. Additionally, the company is advancing OKN-007 as a potential therapy for glioblastoma brain tumors. Beyond its pharmaceutical endeavors, HLB Therapeutics is also involved in the wholesale distribution of vaccines and the production of electrical and electronic components like motors, pumps, and transformers. The company, which established its roots in 2000 and is based in Seongnam, South Korea, underwent a name change in December 2021, transitioning from its former identity as G-treeBNT Co., Ltd. to its current designation.
株価
$1.88
時価総額
$177.26M
変化（1日）
0.00%
変化（1年）
-10.30%
国
KR
取引 HLB Therapeutics Co.,Ltd. (115450)
カテゴリー
Healthcare
の時価総額 HLB Therapeutics Co.,Ltd.(115450)
時価総額: $177.26M
October 2026時点で、HLB Therapeutics Co.,Ltd. の時価総額は $177.26M です。これは、当社のデータによると、HLB Therapeutics Co.,Ltd. が世界で18716th番目に価値のある企業であることを意味します。時価総額は、上場企業の発行済株式の総市場価値であり、企業の価値を測るためによく使用されます。
HLB Therapeutics Co.,Ltd. の時価総額の履歴（2010 から 2026 まで）
